Pasquale Di Letto

Pasquale Di Letto

Auto-generated profile, based on publicly available information

Pasquale Di Letto

Department of Precision Medicine, University of Campania “Luigi Vanvitelli”, Naples, Italy

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2025 in Neurology Genetics
Verified
Journal Article
Open access
PLPasquale Di Letto
Pasquale Di Letto
CLChiara De Leonibus
Chiara De Leonibus
FPFrancesca Pia Palmieri
Francesca Pia Palmieri
MZMariateresa Zanobio
Mariateresa Zanobio
MSMargherita Scarpato
Margherita Scarpato
APAngela Peron
Angela Peron
Neurodevelopmental disorders (NDDs) are often the results of genetic factors, whose identification and key role in their etiology may be elusive. Despite advancements in genetic testing, many cases remain unsolved. Single-nucleotide variants in a critical 18-bp region of the noncoding gene RNU4-2, a crucial component of the spliceosome complex, have been recently recognized as being responsible for ReNU syndrome, also known as NDD with hypotonia, brain anomalies, distinctive facies, and absent language (NEDHAFA). The aim of this study was to investigate the prevalence of RNU4-2 variants within a cohort of unsolved patients exhibiting NDDs from the Telethon Undiagnosed Disease Program (TUDP). We conducted a reanalysis of genomic data using bioinformatic tools, followed by direct sequencing to identify variants in the RNU4-2 critical region. Causative variants were detected in 11 of 375 tested individuals, allowing us to diagnose 2.93% of our unsolved cohort. All heterozygous variants in RNU4-2 occurred de novo, including 10 with the recurrent n.64_65insT insertion and 1 with n.77_78insT. Structural modeling suggested that these variants disrupt the U4/U6 snRNA interaction, potentially impairing spliceosome function. Our findings reinforce the critical role of RNU4-2 variants in syndromic NDDs and underscore the importance of noncoding regions in genetic diagnoses. These findings show that RNU4-2 variants account for approximately 2.9% of the patients with TUDP in this study and highlight the need for integrating advanced molecular techniques and data sharing to refine diagnoses and enhance our understanding of rare genetic disorders.

8 December 2025 in Genes
Verified
Journal Article
Open access
PDF file
MOMaria Elena Onore
Maria Elena Onore
Martina CaiazzaMartina Caiazza
Martina Caiazza
CMCatia Mio
Catia Mio
GSGioacchino Scarano
Gioacchino Scarano
PLPasquale Di Letto
Pasquale Di Letto
Giulio PilusoGiulio Piluso
Giulio Piluso
Background: Cardiomyopathies are a heterogeneous group of heart muscle disorders with diverse genetic origins. Biallelic loss-of-function (LoF) variants in the nebulin-related anchoring protein (NRAP) gene have been linked to dilated cardiomyopathy (DCM) and left ventricular noncompaction cardiomyopathy, though only a few families have been described. NRAP, a member of the Nebulin family, plays a key role in cardiomyocyte development, structural integrity, and muscle function. Methods: We investigated two Italian siblings with DCM born to consanguineous parents from a small village in Campania. Exome sequencing, homozygosity mapping, and comparative analyses with other reported cases were performed. Genealogical research was conducted using civil registry data to reconstruct extended family pedigrees. Results: Both siblings were homozygous for a LoF variant in NRAP (NM_198060.4:c.619del; p.Val207TrpfsTer20). A third brother with tachycardia-induced cardiomyopathy, as well as their living mother, who did not have cardiac abnormalities, were found to be heterozygous. The same homozygous variant was recently identified in another Italian family with DCM coming from North-eastern Italy, whose proband also originated from a nearby village in Campania. These two families exhibited heterogeneity in clinical presentation. Homozygosity analysis revealed a >25 Mb shared region on chromosome 10 encompassing NRAP, supporting a common ancestral origin. While genealogical reconstruction did not allow identification of a shared ancestor, it confirmed consanguinity and enabled the recognition of potential carriers across both families. Conclusions: Our findings strengthen the evidence for NRAP as a disease-causing gene in cardiomyopathies and highlight a likely founder effect in Campania. Incorporating NRAP into genetic testing panels is warranted, especially in populations with high rates of consanguinity or suspected founder variants.

1 January 2025 in Human Mutation
Verified
Journal Article
Open access
MZMariateresa Zanobio
Mariateresa Zanobio
FNfrancesca nardecchia
francesca nardecchia
GCGerarda Cappuccio
Gerarda Cappuccio
MOMaria Elena Onore
Maria Elena Onore
PLPasquale Di Letto
Pasquale Di Letto
ATAnnalaura Torella
Annalaura Torella
Hypomyelinating leukodystrophies are a heterogeneous group of disorders characterized by abnormal myelin formation in the central nervous system. Thanks to the increased use of NGS, a growing number of pathogenic single nucleotide variants in DEGS1 have recently been reported to be responsible for hypomyelinating leukodystrophy 18 (HLD18), a rare and severe autosomal recessive form. DEGS1 is a small gene (4 exons and 17 kb) encoding Δ4‐dihydroceramide desaturase, which catalyzes the final step in ceramide biosynthesis. Here, we present two patients from unrelated families affected by severe and progressive white matter disease with developmental delay with or without regression and severe intellectual disability. Trio exome sequencing (ES) revealed in both probands two homozygous missense variants in the DEGS1 gene, p.Asp16His and p.Asn255Ser, both inherited from their heterozygous healthy mothers and with a noncarrier father. This curious finding of inconsistent segregation data raises the need for further testing. There is no MLPA test available for this gene, as no deletions have been reported. However, we tried a customized high‐resolution 1 M CGH array, which was surprisingly positive in both cases: a 63‐kb heterozygous deletion encompassing the entire gene in one proband and a 7‐kb heterozygous deletion of Exons 2–3 in the second case. Previously reported cases of HLD18 have all been found to carry single nucleotide pathogenic variants in DEGS1, and the two patients described here are the first to carry whole or partial microdeletions involving DEGS1 that unmask pathogenic missense variants on the other allele. These two cases report the first examples of microdeletions of DEGS1 that unmask recessive allele pathogenic variants, underscoring the importance of considering whole or partial gene deletions in the diagnostic pipeline.

10 March 2025 in American Journal of Medical Genetics Part A
Verified
Journal Article
Open access
PLPasquale Di Letto
Pasquale Di Letto
ABAlberto Budillon
Alberto Budillon
SRSarah Iffat Rahman
Sarah Iffat Rahman
FBFrancesca Del Vecchio Blanco
Francesca Del Vecchio Blanco
MZMariateresa Zanobio
Mariateresa Zanobio
ATAnnalaura Torella
Annalaura Torella
Sotos syndrome is a rare genetic disorder characterized by distinctive facial features, including a broad and prominent forehead, dolichocephaly, and learning disabilities ranging from mild to severe intellectual impairment. Affected individuals often show overgrowth in height and head circumference over two standard deviations. The syndrome is caused by haploinsufficiency of the NSD1 gene, with no evidence of genetic heterogeneity to date. Here we describe the unsolved case of a child of 4 years of age with a clinical diagnosis of Sotos syndrome. However, trio exome sequencing (ES) and exon chromosomal microarray (CMA) analysis excluded both small and large mutations in the NSD1 gene. As part of the Telethon Undiagnosed Programme, we used additional tools to investigate the possibility of new genes or elusive mutations that may have been missed by previous molecular diagnostic approaches. Therefore, we performed Nanopore long‐read sequencing. This revealed a 447 bp insertion in exon 13 of the NSD1 gene. mRNA analysis confirmed in‐frame skipping of exon 13 that encodes for two PHD domains. The genomic insertion shows 100% identity with an intronic region, although inverted, containing an AluSx1 element 2 kb upstream of the skipped exon, which may drive the event by masking the splice acceptor site of exon 13. Interestingly, this is the first case of Sotos syndrome linked to a pathogenic mechanism involving an insertion enclosing a transposable element generating a protein devoid of two PHDs, which are required for reading histone post‐translational modifications.

25 March 2026 in Genetics in Medicine Open
Verified
Journal Article
Open access
ATAnnalaura Torella
Annalaura Torella
MMManuela Morleo
Manuela Morleo
CSCarmine Spampanato
Carmine Spampanato
RCRaffaele Castello
Raffaele Castello
MZMariateresa Zanobio
Mariateresa Zanobio
ATAntonio Trabacca
Antonio Trabacca
Many children with severe genetic disorders remain undiagnosed despite advanced genomic technologies. Early diagnosis is vital for prognosis, genetic counseling, and targeted treatment development. This study aims to increase diagnostic rates in complex pediatric cases and foster research into disease mechanisms. Launched in 2016, the Telethon Undiagnosed Diseases Program provides a structured, multicenter approach to rare disease diagnosis. Standardized case submission criteria ensured consistent clinical data collection. Children with severe, multisystemic disorders and prior negative genetic tests were eligible. After case approval, trio-based exome sequencing was performed, with regular reanalysis for unsolved cases until December 2024. Between June 2016 and December 2023, 1338 cases were submitted by 60 clinicians from 22 Italian centers; 1019 were accepted. A definitive genetic diagnosis was achieved in 49% of cases, implicating 330 genes. Most pathogenic variants (70.2%) were de novo, reflecting demographic trends, such as delayed parenthood. The remainder included autosomal recessive or X-linked variants, with homozygosity observed in 9% of patients. The Telethon Undiagnosed Diseases Program significantly shortened the average diagnostic odyssey of ∼8 years. Children born after 2016 benefited from faster diagnoses. This initiative offers a scalable, cost-effective model for improving diagnosis, guiding treatment, and supporting therapeutic innovation in rare pediatric diseases.